These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28864632)

  • 1.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
    Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
    Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
    Frantellizzi V; Pani A; Ippoliti MD; Farcomeni A; Aloise I; Colosi M; Polito C; Pani R; Vincentis G
    Radiol Oncol; 2019 Dec; 54(1):40-47. PubMed ID: 31855572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
    Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
    Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
    Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H
    Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
    Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
    BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
    Naito M; Ukai R; Hashimoto K
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
    Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
    Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flare phenomenon visualized by
    Zhang X; Nakajima K; Mizokami A; Horikoshi H; Nishimoto K; Hashine K; Matsuyama H; Takahashi S; Wakabayashi H; Kinuya S
    Ann Nucl Med; 2024 Jun; 38(6):428-440. PubMed ID: 38478154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study.
    De Feo MS; Frantellizzi V; Bauckneht M; Farcomeni A; Filippi L; Rizzini EL; Lavelli V; Stazza ML; Di Raimondo T; Fornarini G; Rebuzzi SE; Filippo M; Mammucci P; Marongiu A; Monari F; Rubini G; Spanu A; De Vincentis G
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.